Interleukin-17A facilitates tumor progression via upregulating programmed death ligand-1 expression in hepatocellular carcinoma

doi:10.4251/wjgo.v17.i1.97831

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1011)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-6) series.

Item

Count

PDF

HTML

645

Figures (1-6)

131

Sum=797

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

128

Sum=158

Jan 15, 2025 (publication date) through Mar 7, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Gastrointest Oncol. Jan 15, 2025; 17(1): 97831
Published online Jan 15, 2025. doi: 10.4251/wjgo.v17.i1.97831

Full Size Figure Download Figure

Figure 5 Interleukin-17A inhibited hepatocellular carcinoma cell apoptosis. A: Flow cytometry analysis revealed that interleukin-17A (IL-17A) suppressed hepatocellular carcinoma (HCC) cell apoptosis; B: IL-17A decreased the expression of BAX and increased the expression of Bcl-2 in HCC cells. ^aP < 0.05; ^bP < 0.01. FITC-A: Fluorescein isothiocyanate-area; PE-A: Phycoerythrin-area.

Citation: Yang ZX, Zhang LT, Liu XJ, Peng XB, Mao XR. Interleukin-17A facilitates tumor progression via upregulating programmed death ligand-1 expression in hepatocellular carcinoma. World J Gastrointest Oncol 2025; 17(1): 97831
URL: https://www.wjgnet.com/1948-5204/full/v17/i1/97831.htm
DOI: https://dx.doi.org/10.4251/wjgo.v17.i1.97831